8-K current report · filed Nov 13, 2026

Moderna (MRNA) 8-K Current Report: November 13, 2026

Item 5.02MRNA overview

Short answer

Moderna (MRNA) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Legal Officer Shannon Thyme Klinger retiring, employment continuing through March 31, 2027.

Moderna 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Chief Legal Officer Shannon Thyme Klinger retiring, employment continuing through March 31, 2027
  • Officer resignation effective March 31, 2027, or earlier at Moderna’s designation
  • $1,628,300 severance over 12 months, plus continued COBRA premiums through September 30, 2028
  • Potential litigation-related payments: $2,500,000 tied to Arbutus and Genevant outcomes
  • Up to $5,500,000 additional payment tied to Pfizer and BioNTech litigation results

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Moderna 8-K filings

Get the next MRNA 8-K as it lands

Follow MRNA for push alerts, or ask the research agent what this filing means.